BioMed Research International / 2015 / Article / Tab 2 / Review Article
New and Emerging Strategies in Platelet-Rich Plasma Application in Musculoskeletal Regenerative Procedures: General Overview on Still Open Questions and Outlook Table 2 Main variables of the reviewed studies and factors implicated in PRP efficacy.
Tissue type Study type Blood volume (mL) PRP volume PLT count 6 /μ L PRP) Leukocyte count 4 /μ L) Activators Bone In vitro 51 ± 30 (n = 4) 5.3 ± 6.6 (n = 2) 4.2 ± 6.6 (n = 4) NS Thrombin, CaCl2 , Ca-gluconate (n = 4) In vivo 77 ± 135 (n = 54) 2.6 ± 4.9 (n = 34) 2.3 ± 2.3 (n = 34)
1.4 ± 4.1/μ L (n = 3) Thrombin, CaCl2 , CaCl2 + thromboplastin, Ca-gluconate, and CaCl2 + thrombin (n = 52) Tendon In vitro 93 ± 167 (n = 8) 4.5 ± 3.8 (n = 6) 1.9 ± 2.4 (n = 10) 4 ± 4.1/μ L (n = 2) Thrombin, CaCl2 , Ca-gluconate + thrombin (n = 5) In vivo 17 ± 16 (n = 15) 2.4 ± 1.2 (n = 9) 1.9 ± 1.6 (n = 9) 2 ± 3/μ L (n = 2) Thrombin, CaCl2 (n = 6) Cartilage In vitro 115 ± 61 (n = 3) 1.0 ± n/a (n = 1) 0.9 ± n/a (n = 1) NS Thrombin, CaCl2 In vivo 25 ± 20 (n = 11) 3.1 ± 3.8 (n = 8) 2.8 ± 3.9 (n = 8) NS Thrombin, CaCl2 , Ca, Fibrinogen Thrombin (n = 4) Anterior cruciate ligament In vitro 33 ± 38 (n = 2) NS 0.5 ± 0.2 (n = 3) NS NS In vivo 33 ± 23 (n = 3) 5.0 ± 5.7 (n = 2) 1.6 ± 0.7 (n = 5) NS Thrombin, CaCl2 (n = 1)
